Symptom and quality of life assessment during season undergoing pollen immunotherapy single center study
Main Article Content
Keywords
Allergic rhinitis, subcutaneous allergen immunotherapy, Quality of life, total nasal symptom score, visual analog scale (VAS), pediatrics
Abstract
Background: Allergic rhinitis (AR) is an IgE-mediated inflammatory condition of the nasal mucosa. Allergen immunotherapy (AIT) is the only treatment that can modify disease progression and provide long-term symptom control. This study evaluated symptom burden and health-related quality of life (HRQoL) during the pollen season in pediatric patients treated with subcutaneous pollen immunotherapy (SCIT).
Material and Methods: This prospective, cross-sectional study included children aged 6–18 years who received ≥12 months of AIT between 2014 and 2022. All had isolated pollen allergy and were treated with SCIT. Symptom control was assessed using the Total Nasal Symptom Score (TNSS) and Visual Analog Scale (VAS), while HRQoL was measured using PRQLQ or RQLQ depending on age. Patients were grouped by treatment duration: <36 months and ≥36 months. Results: Forty-seven patients completed questionnaires at least two pollen seasons after their final SCIT dose. Compared with the <36-month group, patients treated for ≥36 months showed significantly lower nasal and ocular symptoms (P < 0.001). Mean TNSS scores were lower (5.42 vs. 9.57, P = 0.018), and more patients had mild symptoms (60.6% vs. 21.4%, P = 0.003). Good symptom control (VAS < 2) was also more frequent (36.4% vs. 14.3%, P = 0.022). HRQoL scores (PRQLQ/RQLQ) were significantly better in the ≥36-month group, particularly in social and school functioning.
Conclusion: SCIT duration ≥36 months is associated with improved symptom control and HRQoL during the pollen season, supporting guideline recommendations of at least 3 years of AIT in pediatric AR.
References
2. Klimek L, Bachert C, Pfaar O, et al. ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergo J Int. 2019;28(7):255–76. https://doi.org/10.1007/ s40629-019-00110-9
3. Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. 2017;140(4):950–58. https://doi. org/10.1016/j.jaci.2017.03.050
4. Tosca MA, Trincianti C, Naso M, Nosratian V, Ciprandi G. Treatment of allergic rhinitis in clinical practice. Curr Pediatr Rev. 2024;20(3):271–77. https://doi.org/10.2174/15733963206 66230912103108
5. Roberts G, Pfaar O, Akdis C, et al. EAACI guidelines on aller-gen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–98. https://doi.org/10.1111/all.13317
6. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721–67. https://doi.org/10.1016/j. jaci.2020.07.007
7. Sultész M, Horváth A, Molnár D, et al. Prevalence of allergic rhinitis, related comorbidities and risk factors in schoolchil-dren. Allergy Asthma Clin Immunol. 2020;16(1):98. https:// doi.org/10.1016/j.jaci.2020.07.007
8. Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69(7):854–867. https:// doi.org/10.1111/all.12383
9. Klimek L, Bergmann KC, Biedermann T, et al. Visual analog scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care. Allergo J Int. 2017;26(1):16–24. https://doi.org/10.1007/s40629-016-0006-7
10. Varni JW, Seid M, Rode CA. The PedsQL™: measurement model for the pediatric quality of life inventory. Medical Care. 1999;37(2):126–39. https://doi.org/10.1097/ 00005650-199902000-00003
11. Memik NC, Agaoglu B, Coskun A, Uneri OS, Karakaya I. The validity and reliability of the Turkish Pediatric Quality of Life Inventory for children 13-18 years old. Turk Psikiyatri Dergisi. 2007;18(4):353.
12. Yuksel H, Yilmaz O, Alkan S, Değirmenci PB, Kirmaz C. Validity and reliability of Turkish version of rhinitis and mini-rhinitis quality of life questionnaires. Allergologia et immunopatho-logia. 2009;37(6):293–97. https://doi.org/10.1016/j.aller.2009. 04.006
13. Alblewi SMS, Alenazi LM, Alshahrani RS, et al. Prevalence of allergic rhinitis and its impact on quality of life among pediatric patients in Tabuk, Saudi Arabia. Oman Med J. 2024;39(6):e696. https://doi.org/10.5001/omj.2024.118
14. Wang C, Bao Y, Chen J, et al. Chinese guideline on aller-gen immunotherapy for allergic rhinitis: the 2022 update. Allergy Asthma Immunol Res. 2022;14(6):604. https://doi. org/10.4168/aair.2022.14.6.604
15. Bao Y, Chen J, Cheng L, et al. Chinese Guideline on aller-gen immunotherapy for allergic rhinitis. J Thorac Dis. 2017;9(11):4607–4650. https://doi.org/10.21037/jtd.2017.10.112
16. Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–798. https://doi.org/10.1111/all.13317
17. Agenäs H, Brorsson AL, Kull I, Lindholm-Olinder A. Treatment with pollen allergen immunotherapy improves health-related quality of life in children and adolescents: a three-year follow-up study. Allergy Asthma Clin Immunol. 2023;19(1):4. https://doi.org/10.1186/s13223-023-00756-9
18. Contoli M, Porsbjerg C, Buchs S, Larsen JR, Freemantle N, Fritzsching B. Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: subgroup analyses of the REACT study. J Allergy Clin Immunol. 2023;152(2):445–452. e444. https://doi.org/10.1016/j.jaci.2023.02.024
19. Field K, Blaiss MS. Sublingual versus subcutaneous immunotherapy for allergic rhinitis: what are the important therapeutic and real-world considerations? Curr Allergy Asthma Rep. 2020;20(9):45. https://doi.org/10.1007/ s11882-020-00934-4
20. Bożek A, Kołodziejczyk K, Jarząb J. Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis. Ann Allergy Asthma Immunol. 2018;120(1):53–58. https://doi. org/10.1016/j.anai.2017.10.009
21. Song Y, Long J, Wang T, Xie J, Wang M, Tan G. Long-term efficacy of standardised specific subcutaneous immunotherapy in children with persistent allergic rhinitis due to multiple allergens including house dust mites. J Laryngol Otol. 2018;132(3):230–35. https://doi.org/10.1017/ S0022215117002547
22. Vieira RJ, Pham-Thi N, Anto JM, et al. Academic Productivity of Young People With Allergic Rhinitis: A MASK-air Study. J Allergy Clin Immunol Pract. 2022;10(11):3008–3017.e4. https://doi.org/10.1016/j.jaip.2022.08.015